Capturing Value from Pharma M&A | Experts at Infiniti Research Unveil Critical Considerations for Success

Download

Capturing Value from Pharma M&A

LONDON--()--A well-known market intelligence company, Infiniti Research, has announced the completion of its latest article - why pharma M&A is a driver of strategic repositioning.

“Pharma M&A has become a common practice for companies that have non-diverse pipelines or have top revenue drugs that are nearing patent expiration and subsequent generic erosion,” says a market research analyst at Infiniti Research.

The pharmaceutical industry is one of the major sectors that is actively involved in huge mergers and acquisition (M&A) deals, both in terms of numbers of deals and the amount of money spent. Most companies in the sector, especially the big pharma consider pharma M&A as a major factor to bolster innovation and overall growth. Recent research by our pharma industry experts shows that revenues coming from innovations sourced outside of Big Pharma is currently stands at over 45%. Over the years, several large, game-changing deals have continuously and profoundly changed the competitive landscape of the sector, while smaller yet significant transactions remain an integral part of pharma industry operations.

The COVID-19 outbreak has caused a significant threat to global pharmaceutical industry. Our business continuity support solutions can help you to combat the business impact of COVID-19. Request a FREE proposal here.

According to industry experts at Infiniti Research, some of the key consideration for successful M&A include:

  • Achieving Successful Integration Post Pharma M&A: Approximately only 60% of pharma merger deals succeed in the long run. A successful merger is one wherein the resulting company achieves the strategic intentions driving the merger when the deal was initially formed. Mergers that fail often show traits including focusing more attention on back-office integration, cost control, and systems consolidation.
  • Creating business synergies: Revenue increases during pharma M&A can often more difficult to achieve and take longer than expected. During pharma mergers and acquisitions teams must develop strategies such as the degree to which the existing portfolios need to be rationalized, how teams can be used to increase efficiency, how salesforce can be consolidated to remove overlap, and how the projects of each of the brands can be enhanced.
  • Defining the integration strategy: The successful integration of two companies largely depends on having a consistent approach with strategic intent. Guiding principles, priorities, and governance must reflect the logic behind the merger. A reliable integration strategy must be efficient in articulating both financial and nonfinancial goals, as well as risk-mitigation strategies.

Contact us to know the potential impact of COVID-19 on your business and for action plans to respond to the coronavirus crisis.

About Infiniti Research

Established in 2003, Infiniti Research is a leading market intelligence company providing smart solutions to address your business challenges. Infiniti Research studies markets in more than 100 countries to help analyze competitive activity, see beyond market disruptions, and develop intelligent business strategies. To know more, visit:https://www.infinitiresearch.com/about-us

Contacts

Infiniti Research
Anirban Choudhury
Marketing Manager
US: +1 844 778 0600
UK: +44 203 893 3400
https://www.infinitiresearch.com/contact-us

Release Summary

Infiniti Research has announced the completion of their latest article - why pharma M&A is a driver of strategic repositioning.

Contacts

Infiniti Research
Anirban Choudhury
Marketing Manager
US: +1 844 778 0600
UK: +44 203 893 3400
https://www.infinitiresearch.com/contact-us